Meridian wins Cambridge Biotech enteric product line
This article was originally published in Clinica
Meridian Diagnostics (US) is to buy Cambridge Biotech's enteric product line for $5.5 million cash. The deal replaces an agreement formed with Carter-Wallace in May for the purchase of the products for $4.5 million cash (see Clinica No 705, p 1). Cambridge Biotech was instructed by the bankruptcy court to open the offer to bidding.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.